Frontier Medicines: tapping binding pockets across the proteome

Having found “hotspot” binding pockets in more than 20,000 proteins, Frontier Medicines is targeting these sites with a diverse library of starting points for small molecules, targeted protein degraders and autophagy inducers.

Founded in 2018 based on chemoproteomics technology developed at University of California Berkeley, Frontier Medicines Corp. raised a $67 million series A round  in 2019, and announced a $55 million upfront deal with AbbVie Inc. (NYSE:ABBV) in December...